Parkinson's disease: N. Wood and J. R. Vaughan, The National Hospital for Neurology and Neurosurgery, London, UK; A. Brice To conclude, the finding (1) of a reduced loss of FG-labeled neurons in the SN of GDNF-treated rats does not necessarily imply a neuroprotective action of GDNF. A control in which the injection of FG is made after the complete or nearly complete degeneration of the SN neurons would seem to be necessary to definitelyResponse: In our study (1), we injected FG into the striatum in order to retrogradely label a subpopulation of dopaminergic (DA) neurons in the SN. We injected 6-OHDA into the same site 7 days later, so that the FG-labeled DA neurons would be those most susceptible to the lesion. This research design allowed us to identify DA neurons that project specifically to this site without relying on their phenotype. Relevant to this rationale are studies showing that DA neurons, as identified solely by tyrosine hydroxylase (TH), "disappear" when lesions are induced with 6-OHDA and then "reappear" after injection of GDNF protein (2) . In our study, the reduction of FG ϩ neurons in the SN in control groups after treatment with 6-OHDA confirmed that these cells died and did not merely lose phenotypic marker expression. Microglia and other small cells were labeled with FG, which suggests either that these were cells that had phagocytosed degenerating FG ϩ neuronal debris or were shrunken, degenerating DA neurons. Rats treated with an adenoviral vector (Ad) that encodes GDNF had significantly more large FG ϩ neurons in the SN 42 days after injection of 6-OHDA than were found in control rats-an average of 79% (Ad GDNF) as opposed to 31% (controls) [see figure 3 in (1)]-which we interpreted as protection of these FG ϩ DA neurons by Ad GDNF. Pallini et al. offer an alternative explanation that FG ϩ DA neurons degenerated and released FG, and that increased concentrations of GDNF promoted the uptake of FG by neighboring DA neurons. Because only a subpopulation of DA neurons in the SN were labeled with FG, it is possible that FG released by dying neurons could have been taken up by neighboring unlabeled neurons. However, the observed anatomical distribution of FG ϩ neurons argues against this possibility. On the unlesioned side, FG ϩ DA neurons were located in the ventral and medial SN through the rostrocaudal extent of the SN. In the anterior portion of the SN, nearly every DA neuron in the ventral SN was FG ϩ [ figure 2C in (1)]. The distribution of FG ϩ neurons was unchanged in the Ad GDNF group [ figure 2D in (1) Pallini et al. also suggest that injection of FG, after the degeneration of SN neurons had occurred, would demonstrate the protective effect of Ad GDNF. However, we did not observe any obvious differences among the various treatment groups in the size of the 6-OHDA lesion in the striatum, as indicated by the density of TH fiber staining (1) . This suggests that Ad GDNF delivered near the SN did not protect DA nerve terminals from striatal 6-OHDA, as was also reported after injection of GDNF protein near the SN (3). Injection of FG after 6-OHDA would likely lead to little retrograde transport to the SN as DA nerve terminals would have been destroyed. If the striatal lesion volume had been reduced by GDNF treatment, this could have been caused by protection of nerve terminals or induction of sprouting into the denervated area. These possibilities might be distinguished by labeling with FG before the lesion, with subsequent injection of another tracer after the lesion. Consequently, if FG had been injected at the end of the experiment as suggested by Pallini et al., this would have labeled only those DA neurons whose fibers had spouted or remained in the lesion site, defeating the original purpose of the labeling.
